iShares Biotechnology ETF (IBB) is a healthcare and biotech ETF. As of October 28, 2026, ETF Copilot scores IBB 4.3 out of 10 — highest on Growth (9.5), lowest on Value (0.2). It trades at 28.9 times earnings, against its own median of 21.6. Its ten largest holdings are 51% of the fund.
What stands out in IBB's data
U.S. biotechnology stocks, tracked through a broad industry benchmark.
Trades at a richer price than its own history or similar funds — you pay more for each dollar of earnings.
Its trailing EBITDA multiple of 23.6x lands in the priciest 10% of the category, far above the 17.5x peer median, while its 19.5% EBITDA margin trails the 21.9% norm — you pay a premium for a business that earns less than its rivals.
A broad biotech allocation that trades narrower margins for wide industry coverage.
Why did IBB move this week? It rose 2.3% in the week to October 28, 2026 — Genmab A/S and Gilead Sciences drove it
IBB rose 2.3% in the week to October 28, 2026. The holdings that moved it most were Genmab A/S (+44.8%), Gilead Sciences (+3.7%) and Amgen (+3.1%); Moderna (−12.9%) pushed the other way.
How is IBB rated? ETF Copilot scores iShares Biotechnology ETF (IBB) 4.3 out of 10
As of October 28, 2026, ETF Copilot scores iShares Biotechnology ETF (IBB) 4.3 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 4.3 / 10
- Growth: 9.5 / 10
- Value: 0.2 / 10
- Risk: 2.8 / 10
- Quality: 0.9 / 10
- Return: 5.0 / 10
Is IBB expensive right now? It trades at 28.9 times earnings, against its own median of 21.6
As of October 28, 2026, IBB is more expensive than 88% of its own last 7 years.
Trailing 12 months, built from IBB's holdings. How we calculate this →
What's inside IBB?
What's inside IBB: Size (Large 57%, Mid 31%, Small 13%); Geography (International 14%, US 86%); AI 0.9%.
What are IBB's top holdings? The ten largest are 51% of the fund
Gilead Sciences, Amgen, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna, Natera, Argenx SE, Illumina, Biogen and Revolution Medicines are IBB's largest holdings, in that order.
Less concentrated than 53% of Health & Biotech ETFs.
Half of IBB's weight sits in its 10 largest positions, and once those weights are taken into account it behaves like 29 equally weighted holdings.
What is IBB's expense ratio? 0.44% a year
As of October 28, 2026, IBB charges 0.44% a year, yields 0.14% and holds $11.0B in assets across 240 positions.
| Measure | IBB |
|---|---|
| Expense ratio | 0.44% |
| Dividend yield | 0.14% |
| Assets under management | $11.0B |
| Holdings | 240 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “iShares Biotechnology ETF (IBB) scores and holdings analysis”, as of October 28, 2026.
https://etf-copilot.com/etf/ibb
ETF Copilot Pro unlocks IBB's price and what each holding weighs.
Try Pro free →